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ABSTRACT
Telomeres, the physical ends of eukaryotic chromo-
somes, are transcribed into telomeric repeat-
containing RNA (TERRA), a large non-coding RNA,
which forms an integral part of telomeric hetero-
chromatin. In vitro, naked TERRA molecules are ef-
ficient inhibitors of human telomerase, base-pairing
via their 50-UUAGGG-30 repeats with the template
sequence of telomerase RNA, in addition to contact-
ing the telomerase reverse transcriptase protein
subunit. In vivo, however, TERRA-mediated inhib-
ition of telomerase can be prevented by unknown
mechanisms. Also, heterogeneous nuclear ribo-
nucleoprotein A1 (hnRNPA1) has been implicated
in telomere length control. In vivo, TERRA is partially
associated with hnRNPA1, and hnRNPA1 is also
detected at telomeres. We demonstrate that on
binding of TERRA, hnRNPA1 can alleviate the
TERRA-mediated inhibition of telomerase.
However, when in excess over TERRA, hnRNPA1
becomes itself an inhibitor of telomere extension,
on binding of the telomeric DNA substrate. Yet,
hnRNPA1 has no notable direct effects on the tel-
omerase catalysis. Our in vitro results suggest that
TERRA-mediated telomerase inhibition may be pre-
vented by hnRNPA1 in vivo. Telomere extension by
telomerase may require balanced levels of TERRA
and hnRNPA1 at telomeres. Thus, TERRA and
hnRNPA1 can function as a bimolecular regulator
to turn telomerase and the telomere on and off.
INTRODUCTION
Telomeres protect chromosome ends from DNA repair
activities that reseal chromosome internal DNA breaks
that occur during DNA damage (1). Telomeric DNA
shortens with every round of semiconservative DNA rep-
lication due to the end replication problem and nucleolytic
processing. Short telomeres induce cellular senescence.
The telomerase enzyme can solve the end replication
problem, re-extending telomere 30 ends by reverse
transcribing the template region of its tightly associated
RNA moiety into telomeric repeats (2–4). The regulation
of telomerase at chromosome ends is not well understood
and is the subject of intensive investigations in several
laboratories (5,6).
Telomeres are transcribed in most or all eukaryotes into
the long non-coding RNA TERRA (7). TERRA transcrip-
tion starts in the subtelomeric region and proceeds toward
chromosome ends. Thus, TERRA contains near its 30 end
telomeric repeats in the form of RNA. The UUAGGG-
repeat containing RNA molecules act as potent mixed-
type inhibitors of human telomerase in vitro (8,9).
However, it is unclear under which circumstances
TERRA may regulate telomerase in vivo. Supporting a
role of TERRA in telomerase control, it was found that
in human cells TERRA is displaced or degraded at telo-
meres by factors involved in nonsense mediated RNA
decay (NMD). Although more abundant in the cytoplasm,
NMD factors are detected at low levels in the nucleus,
physically interacting with the telomeric chromatin (10)
and also with telomerase (11–14). On the other hand,
elevated TERRA transcription at human telomeres did
not prevent telomerase-mediated telomere extension (15).
In Saccharomyces cerevisiae, induction of TERRA leads to
telomere shortening. However, this involves activation of
the chromosome end trimming exonuclease 1 at chromo-
some ends rather than inhibition of telomerase (16).
HnRNPA1 is a multifunctional RNA-binding protein
involved in the regulation of RNA biogenesis. Interes-
tingly, hnRNPA1 is also involved in telomere mainten-
ance (17). Mouse cells deﬁcient for hnRNPA1 have
short telomeres, and this phenotype was rescued upon ex-
pression of hnRNPA1 from a cDNA. HnRNPA1 binds
single-stranded human d(TTAGGG)n telomeric DNA
repeats in vitro (18,19) as well as r(UUAGGG)n telomeric
RNA repeats that are contained within TERRA (8,19,20).
HnRNPA1 (21,22) or fragments thereof (17) also associ-
ate with telomerase activity. Finally, it has been proposed
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that a switch at telomeres from replication protein A (RP-
A) for DNA replication in S phase to protection of
telomeres 1 (POT1)/TPP1 after S phase is triggered by
hnRNPA1 and TERRA (23). In vitro, hnRNPA1 can
compete with RP-A for the binding of the single-
stranded G-strand (23), and an increase in TERRA abun-
dance after S phase may sequester hnRNPA1 from
telomeric DNA. Binding of hnRNPA1 to TERRA may
in turn free the telomeric 30 overhang for binding by
POT1-TPP1. Proteins with sequence homology to
hnRNPA1 and roles at telomeres have also been
reported in S. cerevisiae, but the involved mechanisms
are not known (24).
Here, we show that TERRA and hnRNPA1 cooperate
in telomerase control in vitro. The telomerase-inhibitory
effects of TERRA are alleviated on hnRNPA1 association
with TERRA. On the other hand, we ﬁnd that excess of
hnRNPA1 also inhibits telomerase through binding and
sequestration of the DNA primer, although hnRNPA1
has no notable direct effects on the telomerase catalytic
activity. Our data demonstrate that in vitro telomerase
activity is maintained as long as the levels of TERRA
and hnRNPA1 are balanced. Thus, TERRA and
hnRNPA1 may provide a bimolecular switch to ﬁne-
tune telomerase activity at chromosome ends.
MATERIALS AND METHODS
Plasmids and oligonucleotides
Plasmids for transient transfection of human telomerase
reverse transcriptase (hTERT) (pcDNA6-ZZ-3xFlag-
hTERT) and hTR (pBS-U1-hTR) were described previ-
ously (25). For bacterial expression of hnRNPA1,
pGEX-hnRNPA1 was generated by PCR ampliﬁcation
of the hnRNPA1 open reading frame from pcDNA6-
hnRNPA1 using BamH1-A1_F and A1-EcorRI_R
primers (Supplementary Table S1) and subcloned into
the BamHI and EcoRI sites of pGEX-6P-1 vector (GE
Healthcare). pcDNA6-hnRNPA1 was generated by PCR
ampliﬁcation of the hnRNPA1 open reading frame from
pCMV6-XL5-hnRNPA1 (Origene, clone NM_002136)
using HindIII-A1_F and EcoRI-A1_R primers. cDNAs
were subcloned into retroviral-based pCL vectors for ex-
pression of ZZ or hnRNPA1-ZZ proteins in HT1080 cells.
Oligonucleotides were purchased from Microsynth and
are listed in Supplementary Table S1.
Antibodies
Antibodies against Flag (F1804) and tubulin (T9026, for
western blotting) were obtained from Sigma. The 9B11
antibody against Myc was purchased from Cell Signaling.
Antibodies against hnRNPA1 (SC-32B01), tubulin (SC-
8035, for immunoprecipitation), cyclin E (SC-247) and
cyclin B1 (SC-245) were from Santa Cruz, and antibodies
against GST (27457701) were from GE Healthcare.
Stable cell line generation
HT1080 stable cell lines were generated by viral transduc-
tion and puromycin selection (1 mg/ml).
hnRNPA1 depletion
The 293T cells were transfected for 48 h with siRNAs
against GFP or hnRNPA1 (sequences in Supplementary
Table S1) using Interferin (Polyplus).
Protein expression and puriﬁcation
Rosetta pLysS competent bacteria (Novagen) were trans-
formed with pGEX-hnRNPA1. For expression of recom-
binant GST-hnRNPA1, 2 l of 2YT containing 34 mg/ml
chloramphenicol, 50 mg/ml ampicillin and 50 mg/ml car-
benicillin were inoculated with 50ml of overnight culture
and incubated at 37C until the OD600 reached 0.8.
Protein expression was induced for 3 h at 37C by
adding 0.4mM IPTG. After centrifugation, the bacteria
were washed once with ice-cold 1x PBS. The pellet was
resuspended in 60ml lysis buffer (1x PBS, 1mM DTT and
1x protease inhibitor cocktail EDTA-free from Roche).
The lysate was sonicated ﬁve times for 10 s (Branson
soniﬁer 250, setting 3, constant). Glycerol and Triton X-
100 were added to ﬁnal concentrations of 10 (v/v) and 1%
(v/v), respectively. The extract was incubated on a rotating
wheel for 15min at room temperature and then
centrifuged for 15min at 12 000 g at 4C. The supernatant
was incubated with 2ml 50% slurry of GSH-coupled
beads (GE Healthcare). After binding for 2 h at 4C,
bead-bound proteins were washed once with 1x PBS,
10% (v/v) glycerol and three times with 1xPBS. GST-
hnRNPA1 was eluted for 30min at 4C with 2ml 20mM
NaCl, 20mM GSH and 200mM Tris–HCl (pH 9.5).
Glycerol was added to a ﬁnal concentration of 10%
(v/v). To remove the remaining beads, the eluate was
passed through a 35 mM ﬁlter (Mobitec). The same
protocol was applied to express and purify GST alone
using pGEX-6P-1 vector with the only exception that
the elution steps were performed with 20mM GSH and
200mM Tris–HCl (pH 7.5). The second puriﬁcation step
was performed on a HiTrapQ HP 1ml column using the
Akta puriﬁer system and the Unicorn software (GE
Healthcare). Before loading, each eluate from the ﬁrst
puriﬁcation step was diluted 10x in 20mM Tris–HCl
(pH 8.0) and 25mM NaCl. A 20ml NaCl gradient was
applied from 25mM to 1 M. 500 ml fractions were col-
lected, glycerol was added to 10% (v/v) ﬁnal concentra-
tion and samples were quick-frozen.
Telomerase puriﬁcation
For telomerase overexpression, Human Embyronic
Kidney (HEK) 293E cells were grown in suspension
culture and transiently transfected with pcDNA6-ZZ-
3xFLAG-hTERT and pBS-U1-hTR at the Protein
Expression Core Facility of EPFL (http://pecf.epﬂ.ch/).
Forty-eight hours post-transfection, cells were harvested
by centrifugation. In all, 1.5 108 cells were resuspended
in 12ml 20mM HEPES-KOH (pH 7.9), 2mM MgCl2,
200mM KCl, 10% (v/v) glycerol, 1mM DTT, 1mM
EDTA containing protease inhibitor cocktail (Roche)
and lysed in a dounce homogenizer using 12 strokes
with a type B pestle. Triton X-100 was added to a ﬁnal
concentration of 0.1% (v/v), and the lysate was incubated
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on a rotating wheel at 4C for 30min. The lysate was
cleared by centrifugation at 20 000 g for 15min at 4C.
Telomerase was bound to IgG Sepharose 6 Fast Flow
(GE Healthcare; 50 ml beads per extract corresponding
to 1.5mg total protein) blocked with 0.5mg/ml BSA
and 0.05mg/ml yeast RNA, and equilibrated in 20mM
HEPES-KOH (pH 7.9), 2mM MgCl2, 300mM KCl,
10% (v/v) glycerol, 1mM DTT, 1mM EDTA, 0.1%
(v/v) Triton X-100, 1mM PMSF. After overnight
binding at 4C, beads were washed twice in the same
buffer, once with 50mM Tris–HCl (pH 7.4), 100mM
NaCl, 2mM MgCl2, 0.1% (v/v) Triton X-100, 10% (v/v)
glycerol, and once with 50mM Tris–HCl (pH 7.4),
300mM NaCl, 2mM MgCl2, 0.1% (v/v) Triton X-100,
10% (v/v) glycerol. Telomerase was eluted for 2 h at RT
in 45 ml of the same buffer containing 0.11U/ml AcTEV
protease (Invitrogen). The eluate was passed through a
35 mM ﬁlter (Mobitec) by centrifugation, and samples
were quick-frozen.
Gel mobility shift assay
PAGE-puriﬁed RNA and DNA oligonucleotides were re-
suspended in RNase-free water. Oligonucleotides were 50
end-labeled with [32P]-g-ATP (3000Ci/mmol) using T4
polynucleotide kinase (NEB), and unincorporated nucleo-
tides were removed using mini Quick Spin RNA Columns
(Roche). RNA– or DNA–protein complexes were
separated on native 8% polyacrylamide gels that were
run in 0.5x TBE buffer at 4C (350V for 1 h). The gels
were pre-run for 30min at 350 V. The gels were dried and
exposed to a PhosphoImager screen. Signals were
quantiﬁed by Image Quant. For protein binding to (UU
AGGG)3, 2 nM [
32P] 50 end-labeled (UUAGGG)3 was
incubated for 30min at 30C in 1x EMSA buffer
[50mM Tris–HCl (pH 8.0), 50mM KCl, 1mM spermi-
dine, 1mM MgCl2, 0.8mg/ml deacetylated-BSA, 0.5mM
DTT and 10% (v/v) glycerol] with the indicated
amounts of GST or GST-hnRNPA1 or 1 ml of the
protein dilution buffer [20mM Tris–HCl (pH 8.0),
215mM NaCl, 10% glycerol], ±200 ng a-hnRNPA1
antibody. For the determination of the KD of GST-
hnRNPA1 for (UUAGGG)3 or (TTAGGG)3, GST-
hnRNPA1 (12.5, 25, 37.5, 62.5, 75, 87.5, 112.5 or
137.5 nM) was incubated with 2 nM [32P] 50 end-labeled
(UUAGGG)3 in EMSA 1x buffer for 45min at 30
C.
Reactions were placed on ice and loaded on native 8%
polyacrylamide gels in 0.5x TBE at 4C. For the compe-
tition experiments, competitor RNAs were added as
indicated before the addition of GST-hnRNPA1.
Moreover, rA18 was always added to reach the same
ﬁnal oligonucleotide concentration in each reaction.
Direct telomerase activity assay and rescue experiment
To test effects of hnRNPA1 on telomerase activity, direct
telomerase assays (DTA) were performed using enriched
telomerase fraction and the 50 end biotinylated telomerase
substrates B-(TTAGGG)3 and B-TS (Supplementary
Table S1). DTA was performed as previously described
(25). Reactions were assembled on ice in 20 ml ﬁnal
volumes. They contained 35 nM biotinylated substrate
DNA oligonucleotide, 175 nM RNA oligonucleotides
(mixture of (UUAGGG)3 and rA18 as indicated), 40 mM
dATP, 80 mM dTTP, 2 mM dGTP, 20 mCi of a-[32P]-dGTP
(3000Ci/mmol), 53mM Tris–HCl (pH 8.0), 50mM KCl,
45mM NaCl, 1mM MgCl2, 1mM spermidine, 1.7%
glycerol, 5mM b-mercaptoethanol, 0.8mg/ml deacetyla-
ted-BSA and 5U SUPERaseIn (Ambion). Telomerase
and dNTPs were added last to the reactions. Buffer com-
position was maintained constant in all the reactions. The
reaction was incubated for 45min at 30C and stopped by
addition of EDTA to 25mM, mixed with 30 end
biotinylated and [32P] 50 end-labeled 10-mer (used as a
recovery and loading control) before the puriﬁcation
step of the elongated products on paramagnetic M-270
streptavidin beads (Invitrogen). After washing, bead-
bound products were resuspended in 12 ml of sample
loading buffer and denatured at 95C for 3 min;6 ml was
separated on denaturing (7M urea) 1x TBE 12% poly-
acrylamide gels. Dried gels were exposed to a
PhospoImager screen. Signals were quantiﬁed by Image
Quant.
Immunoprecipitation from cell extracts and RNA
extraction
All steps were performed at 4C unless stated otherwise.
For Figure 1, immunoprecipitations from enriched
nuclear extracts were performed as described before (8),
with slight modiﬁcations: for the washing steps after the
overnight immunoprecipitation, the beads were ﬁrst
washed three times with B1/2 NP40 [10mM HEPES (pH
7.5), 200mM NaCl, 0.5mM EGTA, 0.5mM EDTA,
0.5mM DTT, 0.25mM PMSF and protease inhibitor
cocktail (Roche), 0.6% (v/v) NP40] and then washed
twice with buffer B1/2 without NP40. Beads were resus-
pended in 200 ml buffer B1/2 NP40 containing 10% (v/v)
glycerol. Protein fractions were loaded on a 4–20%
gradient Tris–HCl Precast Gel (Bio-Rad). RNA was ex-
tracted with Trizol-LS (Invitrogen). After precipitation
and washes, the RNA was resuspended in 8 ml of H2O
and DNase-treated following the Nucleospin Macherey
Nagel kit protocol. After DNase treatment at 37C for
10min, 1.2 ml 10mM EDTA was added and DNase was
heat inactivated at 75C for 20min.
RNA chromatin immunoprecipitations
RNA chromatin immunoprecipitations (RNA-ChIP)
assays were performed as described (http://www.pro
tocol-online.org/cgi-bin/prot/view_cache.cgi?ID=3241)
with minor modiﬁcations. Brieﬂy, 106 cells/ml in 1x PBS
were cross-linked for 10min with 1% formaldehyde.
Glycine was added to a ﬁnal concentration of 125mM
to quench cross-linking, and the cells were collected at
500 g for 5min. The cell pellet was washed with cold
PBS, resuspended in 200 ml of buffer A [5mM PIPES
(pH 8.0), 85mM KCl, 0.5% NP40, protease inhibitors
cocktail (Roche), 50U/ml SUPERasein] and placed on
ice for 10min. Nuclei were collected by centrifugation at
2 400 g for 5min at 4C, washed in buffer A without NP-
40 and resuspended in 500 ml of 1% SDS, 10mM EDTA,
50mM Tris–HCl (pH 8.1), protease inhibitors cocktail
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(Roche), 50U/ml SUPERasein; they were then incubated
on ice for 10min. The Diagenode bioruptor was used for
sonication (settings high, ﬁve cycles of 30 sec on and 30 sec
off in ice-cooled water). The lysates were cleared by
centrifugation at 12 000 g for 15min at 8C, and diluted
5-fold in IP buffer [0.01% SDS, 1.1% Triton X-100,
1.2mM EDTA, 16.7mM Tris–HCl (pH 8.1), 167mM
NaCl, protease inhibitors cocktail (Roche), 50U/ml
A
B
C
α-Myc
α-Tub   α-Myc
IP (1/10)I 
(1/8.5)
I 
(1/8.5)
vector hnRNPA1-Myc
α-Tub   α-Myc
IP (1/10)
IP efficiency (%)                                                     98
Probe :        TERRA                                 Centromeric
vector
hnRNPA1-Myc
 
In
pu
t
0.0
10.0
20.0
30.0
    vector     hnRNPA1-Myc
TERRA
R
N
A 
(%
) Centromeric
α
-
tu
bu
lin
α
-
m
yc
 
In
pu
t
α
-
tu
bu
lin
α
-
m
yc
TERRA probe
U2 probe
longer exposure
Input
IgG
CHIP SN
ve
ct
or
A1
-z
z
A1
-z
z
A1
-z
z
Input
IgG
CHIP SN
+ RNase
0.00
0.04
0.08
0.12
0.16
0.20
vector A1-zz
TERRA
U2
***
R
N
A 
(%
)
CHIP
SN
Input α-tubulin α-hnRNPA1
CHIP
SN
TERRA
probe
U2
probe
Input α-tubulin α-hnRNPA1
+ RNase
α-tubulin
α-hnRNPA1
0.8   1    0.3relative amount
siRNA :
siRNA :
0
1
2
3
4
5
6
7
α-tubulin α-hnRNPA1
TE
R
R
A 
(%
)
ve
ct
or
ve
ct
or
ve
ct
or
A1
-z
z
A1
-z
z
A1
-z
z
ve
ct
or
ve
ct
or
- GFP A1
- GFP A1 - GFP A1 - GFP A1 - GFP A1 - GFP A1 - GFP A1
- GFP A1 - GFP A1
Figure 1. Endogenous TERRA is bound to hnRNPA1. (A) Immunoprecipitation of hnRNPA1-myc in 293T nuclear extract. TERRA and centro-
meric RNA were detected by dot blot hybridization. Immunoprecipitation efﬁciency was determined by western blotting. Twenty-ﬁve percent of the
RNA extracted from the input (I) and all RNA from the immunoprecipitates were spotted on the membrane and quantiﬁed. Bars represent the
means±SD of three independent experiments. (B) RNA-ChIP of TERRA associated with endogenous hnRNPA1 in 293T cells untreated () or
transfected with siRNA against GFP or hnRNPA1. RNA was detected by dot blot hybridization. One percent of the input RNA or supernatant and
half of the RNA from the immunoprecipitates was loaded. The same samples were treated with RNase A before loading (+RNase). Bars represent
the means±SD of three independent experiments. (C) RNA-ChIP of TERRA associated with hnRNPA1-ZZ in HT1080 cells. RNA was detected as
in (B). One percent of the input RNA or supernatant and half of the RNA from the immunoprecipitates was loaded. ***P=0.0002. Bars represent
the means±SD of six independent experiments.
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SUPERasein; 4 106 cells per IP]. Before the
immunoprecipitation, a pre-clearing step was performed
for 1 h on a rotating wheel at 4C using Sepharose 6
Beads (Sigma). The pre-cleared extracts were incubated
with 5 mg of antibody for 2.5 h at 4C on a rotating
wheel and Sepharose 6 protein-G beads were added and
tubes were placed at 4C overnight on a rotating wheel.
Beads were washed ﬁve times (1ml wash, 5min each) with
the following buffers. First, in 0.1% SDS, 1% (v/v) Triton
X-100, 2mM EDTA, 20mM Tris–HCl (pH 8.0) contain-
ing 150mM NaCl. Second, in the same buffer containing
500mMNaCl. Third, with 250mM LiCl, 1% (v/v) NP-40,
1% Na-deoxcholate, 1mM EDTA, 10mM Tris–HCl (pH
8.0). Fourth and ﬁfth, with 1mM EDTA, 10mM Tris–
HCl (pH 8.0). Elution was done with 100 ml of 50mM
Tris–HCl (pH 8.0), 5mM EDTA and 1% SDS. After 2 h
incubation at 70C to reverse the cross-link, RNA was
isolated using the RNeasy kit (Qiagen) including a
DNaseI treatment on the column for 30min at RT.
Before loading onto positively charged nylon membrane
(GE Healthcare), all samples were denatured for 5min at
65C in RNA loading buffer (Qiagen RNeasy Kit).
TERRA was detected with a TERRA-speciﬁc probe
prepared as described (10). For detection of U2 snRNA
or centromeric RNA, oligonucleotide probes (Supplemen-
tary Table S1) were 50 end-labeled with 32P.
Cell cycle synchronization
HeLa cells were synchronized in early S-phase using a
double-thymidine block. Cells were seeded at 10%
conﬂuency. After 24 h, thymidine was added to the
medium to a ﬁnal concentration of 2mM. After 18 h,
cells were released by washing three times with PBS and
addition of fresh medium. Nine hours after release, thy-
midine was added again to a ﬁnal concentration of 2mM.
After further 17 h, cells were collected (sample ‘0 h’) or
released as after the ﬁrst block, followed by collection at
2-h intervals. For cell collection, cells were detached by
trypsinization and washed with PBS. Aliquots of cells
were removed and resuspended in SDS-PAGE sample
buffer for subsequent western blot analysis of protein
content, or ﬁxed with cold 70% ethanol for ﬂuorescence-
activated cell sorting analysis of synchronization.
RESULTS
TERRA ribonucleoprotein particles contain hnRNPA1
Immunoprecipitation assays with antibodies against en-
dogenous hnRNPA1 protein indicated association of
TERRA with hnRNPA1 (8,20). To conﬁrm the speciﬁcity
of these results, we expressed myc-tagged hnRNPA1 from
transiently transfected plasmids in (HEK) 293T cells. Two
days post-transfection, we prepared nuclear extract as
described (8) and immunoprecipitated hnRNPA1 with
anti-myc monoclonal antibody (Figure 1A). Immunopre-
cipitation efﬁciency of hnRNPA1 was determined on a
western blot, and TERRA was quantiﬁed by dot blotting
(Figure 1A). Twenty-ﬁve percent of total TERRA was
immunopuriﬁed with myc-tagged hnRNPA1, whereas
only 3% of TERRA was immunopuriﬁed in extracts
derived from empty vector control cells (Figure 1A).
Therefore, TERRA is associated with hnRNPA1 in
nuclear extracts.
To determine whether hnRNPA1 association with
TERRA exists in live cells as opposed to an association
occurring post-lysis in extracts, we carried out RNA-ChIP
experiment. We cross-linked nucleic acids and proteins in
cells with formaldehyde, lysed the cells in presence of 1%
SDS, solubilized complexes by sonication and
immunoprecipitated endogenous hnRNPA1 and tubulin
as a negative control (Figure 1B). After reversal of the
cross-link, TERRA was quantiﬁed by dot blot and U2
snRNA was quantiﬁed as a negative control (Figure 1B).
Approximately 4% of TERRA was immunoprecipitated
with hnRNPA1 antibody in these experiments, whereas
TERRA did not immunoprecipitate with tubulin. U2
snRNA was not detected in the immunoprecipitates.
SiRNA-mediated depletion of hnRNPA1 led to a reduc-
tion of hnRNPA1 to 30% and the fraction of TERRA in
the immunoprecipitates dropped slightly, from 4 to
2.5%. However, the difference was not statistically signiﬁ-
cant, possibly because of insufﬁcient depletion of the
abundant hnRNPA1 protein. Therefore, we repeated the
RNA-ChIP experiment with HT1080 cells that expressed
Protein A-tagged (ZZ) hnRNPA1 from stably transduced
vector (Figure 1C). HnRNPA1-ZZ was puriﬁed over
IgG beads, and TERRA and U2 were quantiﬁed as in
Figure 1B. Although the recovery of TERRA was low in
this experiment, signiﬁcantly more TERRA was puriﬁed
from cells transduced with hnRNPA1-ZZ vector as
compared with empty vector transduced cells
(P=0.0002; Figure 1C). The low recovery rate in the
RNA-ChIP experiments in comparison with the native
immunprecipitation may be due to epitope-tag damaging
that may occur on cross-linking with formaldehyde.
Together, these experiments indicate that TERRA is
associated with hnRNPA1 in vivo.
hnRNPA1 binds with high afﬁnity to UUAGGG
and TTAGGG-repeats
We studied the effects of hnRNPA1 in conjunction with
TERRA on telomerase control. Therefore, we expressed
recombinant GST-tagged hnRNPA1 in Escherichia coli
and puriﬁed it via the tag on glutathione (GSH)-beads.
As a second puriﬁcation step, GST-hnRNPA1 was
fractionated by anion chromatography on a HiTrap Q
HP column. The puriﬁed protein (Figure 2A) was, as
expected, recognized by anti-GST and anti-hnRNPA1
antibodies. The biochemical properties of recombinant
GST-hnRNPA1 were characterized in gel mobility shift
assays (Figure 2B–E), giving results that extend previously
published data (17–19,26,27). GST-hnRNPA1 shifted a 50
end-labeled 50-(UUAGGG)3-30 oligonucleotide, and the
shifted species was further retarded in the gel on
addition of the hnRNPA1 antibody (Figure 2B, compare
lanes 4 and 5). The GST-hnRNPA1 bound telomeric
RNA sequence 50-(UUAGGG)3-30 with a slightly higher
afﬁnity (Kd=27±8nM) than the same sequence (50-(TT
AGGG)3-3
0) in form of DNA (Kd=37±9nM).
However, hnRNPA1 did not bind the non-telomeric
Nucleic Acids Research, 2013, Vol. 41, No. 19 9121
A B
*(UUAGGG)3 - 
GST-hnRNPA1
-*(UUAGGG)3  
supershift  
-    -     Ab  -  Ab
G
ST
G
ST
-
hn
R
N
PA
1
C
*(TTAGGG)3-
*(UUAGGG)3-
- *(TS)
G
ST
-
hn
R
N
PA
1 
 
Bu
ffe
r
G
ST
Bu
ffe
r
Bu
ffe
r
(UUAGGG)3 (TTAGGG)3 TS D
Kd = 37 +/- 9 nM
*(TTAGGG)3-
      GST-hnRNPA1 
Kd = 27 +/- 8 nM
*(UUAGGG)3-
E
*(UUAGGG)3-*(TTAGGG)3-
dA18 TS (TTAGGG)3 rA18 (UUAGGG)3
G
ST
-
hn
R
N
PA
1 
 
G
ST
G
ST
-
hn
R
N
PA
1 
 
G
ST
Bu
ffe
r
      GST-hnRNPA1 
Bu
ffe
r
Bu
ffe
r
      GST-hnRNPA1 
dA18 TS (TTAGGG)3rA18 (UUAGGG)3
      GST-hnRNPA1 
- Bu
ffe
r
-
G
ST
GST-hnRNPA1-  
*oligonucleotide
 
 
G
ST
-
hn
R
N
PA
1
α-hnRNPA1α-GST
G
ST
G
ST
-
hn
R
N
PA
1
- 46
- 58
- 30
- 25
kDa
Coomassie 
20
0
40
0
G
ST
G
ST
-
hn
R
N
PA
1
-175 
- 80 
- 58 
- 46 
- 30 
- 25 
-17 
- 7 
BS
A 
(ng
)
kDa
1 2 17161514131211109876543 18 19 20
1 2 17161514131211109876543 18 19 20
1 2 9876543 1 2 9876543
1 2 1514131211109876543
1 2 543
1 2 43
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(continued)
sequence containing TS oligonucleotide primer (Supple-
mentary Table S1, Figures 2C and D) that was used in
telomerase assays further below. Competition experiments
in which unlabeled oligonucleotides were titrated into the
gel mobility shift assays with labeled telomeric DNA and
RNA (Figure 2E) conﬁrmed the remarkable speciﬁc
binding of single-stranded telomeric DNA and RNA se-
quences by hnRNPA1. Competition was only achieved
when adding unlabeled 50-(TTAGGG)3-30 or 50-(UUAG
GG)3-3
0. Consistent with the Kd-measurements, 50-(UUA
GGG)3-3
0 was a better competitor than the corresponding
DNA oligonucleotide.
hnRNPA1 inhibits telomerase through sequestration
of the primer
We went on to study the effects of hnRNPA1 on telomer-
ase activity. Telomerase was obtained from HEK293E
cells that overexpressed hTERT and hTR (28). The
hTERT subunit carried at the N-terminus tandem protein
A-tags (ZZ) followed by a cleavage site for the TEV pro-
tease and a FLAG-tag. Telomerase was puriﬁed on IgG-
sepharose and eluted by TEV cleavage (Figure 3A). The
TERT protein was detected by western blotting with an
anti-FLAG antibody. Western analysis of the fractions
with an anti-hnRNPA1 antibody revealed that endogen-
ous hnRNPA1 was removed during the puriﬁcation
(Figure 3A).
Telomerase activity was measured in direct telomerase
assays in which the DNA substrates were extended in
presence of a-32P-labeled dGTP and unlabeled dATP
and dTTP. As DNA substrates we used 50-(TTAGGG)3-
30 (Figure 3B, left panel), which can be bound by
hnRNPA1 or the TS-primer (Figure 3B, right panel),
which cannot be bound by hnRNPA1 in its unextended
form (see Figure 2). The TS-primer has been extensively
used in TRAP-telomerase assays (29). Despite its non-
telomeric sequence (50-AATCCGTCGAGCAGAGTT-30;
Supplementary Table S1), TS is a good telomerase sub-
strate, and its three most 30 terminal bases are complemen-
tary to the telomerase RNA template. We used the
TS-primer below as a telomerase substrate, as it cannot
be bound by hnRNPA1 in its unextended form. When
increasing the amounts of hnRNPA1 in the assay with
50-(TTAGGG)3-30, we observed complete blocking of
extension with primer-saturating amounts of GST-
hnRNPA1 (150 nM). However, lower amounts of
hnRNPA1 had no notable effects on the extension of
50-(TTAGGG)3-30. A different result was obtained with
the TS-primer. GST-hnRNPA1 did not inhibit addition
of the ﬁrst 20 nucleotide (nt). However, the +26 nt
product was reduced, and longer extension products
were nearly absent with the highest concentration of
hnRNPA1. This, therefore, indicates that hnRNPA1
prevents telomere elongation when pre-bound to the sub-
strate (Figure 3B, left). In addition, hnRNPA1 inhibits
telomerase during telomere elongation once sufﬁcient
TTAGGG-repeats are added by telomerase to allow the
binding of hnRNPA1 (Figure 3B, right). However, the
unperturbed addition of the ﬁrst 4–5 telomeric repeats to
the TS-primer indicates that hnRNPA1 has no effect on
the enzymatic properties of telomerase, at least as long as
hnRNPA1 cannot bind the DNA substrate. In a time
course experiment with the TS-primer, hnRNPA1 had
also no detectable effects on the kinetics of telomere ex-
tension for the addition of the ﬁrst 4–5 repeats (data not
shown).
hnRNPA1 and TERRA can alleviate their inhibitory
effects on telomerase when balanced
TERRA inhibits telomere elongation on binding of the
telomerase enzyme (8), whereas hnRNPA1 inhibits
telomere elongation on binding of the DNA substrate
(see earlier in text). As hnRNPA1 also binds TERRA,
we investigated their combined effects on telomerase
activity (Figure 4) using 50-(TTAGGG)3-30 or TS as
primer substrates (Figure 4, left and right panels, respect-
ively). As expected, with increasing concentration of
TERRA-oligonucleotide, telomerase activity was in-
hibited with both DNA primers (Figures 4A and C,
lanes 1–4; see Figures 4B and D for the quantiﬁcation).
Presence of puriﬁed GST in the absence of hnRNPA1 had
no effect (Figures 4A and C, lanes 15–18). Addition of
rA18 to the reaction did also not inﬂuence the reaction.
GST-hnRNPA1 again completely inhibited extension of
the 50-(TTAGGG)3-30 primer at 150 nM, whereas for the
TS-primer again only the longer extension products dis-
appeared (Figure 4A, compare lanes 1–2 with 11).
Strikingly, the combined addition of hnRNPA1 and
TERRA could partially or nearly completely suppress
the negative effects on the reaction that we observed
when each component was added individually.
Suppression of inhibition depended on the relative con-
centration of hnRNPA1 and TERRA. For example,
with the TS-primer and hnRNPA1 at 150 nM, the long
Figure 2. Continued
and a-hnRNPA1 Ab. GST-hnRNPA1- (UUAGGG)3 and Ab-GST-hnRNPA1- (UUAGGG)3 complexes (supershift) are indicated. (C) GST-
hnRNPA1 interacts with TERRA RNA and telomeric DNA oligonucleotides but not with the TS primer. EMSA analysis of [32P] 50 end-labeled
(UUAGGG)3, (TTAGGG)3 or TS (2 nM) with puriﬁed GST-hnRNPA1 (35, 105 or 315 nM) or 315 nM GST. (D) GST-hnRNPA1 has similar afﬁnity
for TERRA and telomeric DNA oligonucleotides. EMSA analysis of [32P] 50 end-labeled (UUAGGG)3 or (TTAGGG)3 (2 nM) with puriﬁed GST-
hnRNPA1 (12.5, 25, 37.5, 62.5, 75, 87.5, 112.5 or 137.5 nM). Kds are given and were determined from four independent experiments. (E) EMSA
competition experiments to assess speciﬁcity of hnRNPA1 for TERRA and telomeric DNA oligonucleotides. On the left gel, GST-hnRNPA1
(60 nM) was incubated with [32P] 50 end-labeled (TTAGGG)3 (2 nM) mixed with H2O or 17.5, 35, 175 or 350 nM of non-labeled dA18; 175 or
350 nM TS; 17.5, 35, 175 or 350 nM of (TTAGGG)3; 17.5, 35, 175 or 350 nM of rA18; 17.5, 35, 175 or 350 nM of (UUAGGG)3. On the right gel,
GST-hnRNPA1 (60 nM) was incubated with [32P] 50 end-labeled (UUAGGG)3 (2 nM) mixed with H2O or 17.5, 35, 175 or 350 nM of rA18; 17.5, 35,
175 or 350 nM of (UUAGGG)3; 17.5, 35, 175 or 350 nM of non-labeled dA18; 175 or 350 nM TS; 17.5, 35, 175 or 350 nM of (TTAGGG)3. For both
gels, in lane 1, the radiolabeled oligonucleotide was incubated with the protein buffer only. The vertical line between lanes indicates juxtaposition of
separate parts of the same gel.
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extension products reappeared when TERRA was added
to 175 nM, whereas TERRA alone completely inhibited
telomerase and hnRNPA1 on its own prevented the accu-
mulation of long products (Figure 4A, compare lanes 11
and 14 for the rescue by TERRA from inhibition by
hnRNPA1; compare, for example, lane 4 with lanes 7
and 10 for the rescue by hnRNPA1 from inhibition by
TERRA). Also with the (TTAGGG)3 substrate primer,
telomerase activity was partially rescued when combining
TERRA and hnRNPA1, except for the highest concentra-
tion of hnRNPA1 at which apparently enough hnRNPA1
remained TERRA-free to bind and block extension of (TT
AGGG)3 substrate primer (Figure 4C, lanes 11–14). For
example, with TERRA at 17.5 or 35 nM, addition of
hnRNPA1 to 50 nM roughly doubled the activity (see
Figure 4D for the quantiﬁcation of the results). The
most straightforward interpretation of these results is
that hnRNPA1 and TERRA, when assembling together
into an RNP complex, lose their inhibitory effects on
DNA primer extension and telomerase activity, which
they possess as individual components. The slight
increase of longer reaction products in presence of
TERRA and hnRNPA1 (Figure 4A, lanes 7 and 14) sug-
gested stimulation of repeat addition processivity by
TERRA-hnRNPA1 complexes, but further experiments
will be required to understand the nature of this effect.
hnRNPA1 protein levels do not vary substantially
during the cell cycle
The aforementioned experiments support a model in
which the relative abundance of TERRA and hnRNPA1
determines whether telomerase can elongate chromosome
ends. Therefore, we tested whether hnRNPA1 levels are
regulated during the cell cycle. We synchronized HeLa
cells with a double thymidine block at the G1/S
boundary and collected cells at 2-h intervals after the
release. Protein extracts were prepared, and cell cycle pro-
gression was monitored by following the abundance of
cyclins E and B1 on a western blot (Figure 5A). Cyclin
E peaks during S phase and cyclin B1 in M phase of the
cell cycle. The cyclin analysis indicated that cell synchron-
ization and release were successful and that the samples
covered all stages of the cell cycle. The western blot
analysis of hnRNPA1 indicates that its overall levels are
not strongly regulated during the cell cycle. Thus, whereas
TERRA levels peak in G1 and are low levels in S phase
(30), we do not see corresponding changes in hnRNPA1.
DISCUSSION
In this article, we investigate the combined effects of
hnRNPA1 and TERRA on telomerase activity. Our
studies with hnRNPA1 reveal that this protein does not
perturb the catalytic activity of telomerase as long as it
does not bind the DNA substrate. On primer binding,
however, telomerase extension is blocked. Interestingly,
this mechanism even functions when hnRNPA1 primer-
binding sites are only generated on primer extension by
telomerase. Thus, it seems that hnRNPA1, on binding the
50 end of the extended substrate, can promote the
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dissociation of telomerase from the 30 end which it is ex-
tending (Figure 3B). Alternatively, hnRNPA1 might not
promote telomerase dissociation, but hold onto the
elongating enzyme and prevent it from further extending
the telomeric 30 end. Inhibition of telomerase at a distance
has also been seen with the S. cerevisiae Cdc13p G-
overhang telomere-binding protein (31). Human POT1,
however, inhibits telomerase through sequestration of
the 30 end of the substrate but it does not perturb
telomere extension once telomerase has gained access to
the DNA end (32,33). Our results on hnRNPA1 seem to
rule out a previous proposal based on TRAP assays in
extracts that hnRNPA1 would promote telomere elong-
ation (26). However, our results do not address potential
roles of hnRNPA1 in telomerase assembly (26).
We also ﬁnd that hnRNPA1 and TERRA, which are
partially co-assembled in vivo, can alleviate each other’s
effects on telomere elongation. Our in vitro results support
the existence of three states (Figure 5B). When hnRNPA1
is in excess over TERRA (state 1), it inhibits telomere
elongation through binding of the DNA substrate
(Figure 5B, reaction 1). On the other hand, when
TERRA is more abundant than hnRNPA1 (state 3),
TERRA can bind telomerase and thus inhibit its activity
(Figure 5B, reaction 3). Only when both, hnRNPA1 and
TERRA, are in equilibrium and form inert complexes
(state 2), telomere extension by telomerase can occur
(Figure 5B, reaction 2). It remains unclear under which
conditions the proposed regulatory mechanisms may
occur in vivo. We ﬁnd here that hnRNPA1 is not cell
cycle-regulated, whereas TERRA levels ﬂuctuate
strongly, being low during S phase (30). One could, there-
fore, argue that hnRNPA1 may restrict telomerase action
by DNA end binding during S phase. However, the situ-
ation in vivo likely depends on the local concentrations of
hnRNPA1 and TERRA at a particular telomere at a
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particular time, factors for which we lack the resolution to
experimentally address them. Further complexity is added
to the in vivo situation, as hnRNPA1 may compete for
telomere binding with several other single-stranded
DNA-binding proteins like the telomere-speciﬁc POT1-
TPP1 (34), the DNA replication protein RP-A (23,35) or
the CTC1/STN1/TEN1 (CST) complex (36). Currently, it
is not well understood how binding of these proteins
occurs and how their exchange is regulated. TERRA
seems well suited to promote the exchange of telomere-
binding proteins that have afﬁnity for both telomeric
DNA and RNA (23), and TERRA may be regulated at
individual telomeres to respond to local stress situations.
In addition, it is possible that phosphorylation events or
other post-translational modiﬁcations during the cell cycle
or on DNA damage may regulate the recruitment or
DNA-binding afﬁnities of individual proteins. Whatever
the exact mechanisms, our data demonstrate that
hnRNPA1 can prevent TERRA-mediated inhibition of
telomerase, providing a possible molecular explanation
for why experimental overexpression of TERRA (15,16)
may not be sufﬁcient to inhibit telomerase in vivo.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
The authors thank Claus Azzalin, Sascha Feuerhahn and
Antonio Porro for discussion and Sarah Turnheer and
David Hacker from the protein expression core facility
at EPFL (http://pecf.epﬂ.ch/) for the expression of
telomerase.
FUNDING
Swiss National Science Foundation; a European Research
Council advanced investigator grant [232812]; an Initial
Training Network (ITN) grant (CodeAge) from the
European Commission’s Seventh Framework
Programme [316354]; the Swiss Cancer League and
EPFL. Funding for open access charge: ERC grant.
Conﬂict of interest statement. None declared.
REFERENCES
1. de Lange,T. (2009) How telomeres solve the end-protection
problem. Science, 326, 948–952.
2. Greider,C.W. and Blackburn,E.H. (1985) Identiﬁcation of a
speciﬁc telomere terminal transferase activity in Tetrahymena
extracts. Cell, 43, 405–413.
3. Greider,C.W. and Blackburn,E.H. (1989) A telomeric sequence in
the RNA of Tetrahymena telomerase required for telomere repeat
synthesis. Nature, 337, 331–337.
4. Lingner,J., Hughes,T.R., Shevchenko,A., Mann,M., Lundblad,V.
and Cech,T.R. (1997) Reverse transcriptase motifs in the catalytic
subunit of telomerase. Science, 276, 561–567.
5. Nandakumar,J. and Cech,T.R. (2013) Finding the end:
recruitment of telomerase to telomeres. Nat. Rev. Mol. Cell. Biol.,
14, 69–82.
6. Pfeiffer,V. and Lingner,J. (2013) Replication of telomeres and the
regulation of telomerase. Cold Spring Harb. Perspect. Biol., 5,
a010405.
7. Feuerhahn,S., Iglesias,N., Panza,A., Porro,A. and Lingner,J.
(2010) TERRA biogenesis, turnover and implications for function.
FEBS Lett., 584, 3812–3818.
8. Redon,S., Reichenbach,P. and Lingner,J. (2010) The non-coding
RNA TERRA is a natural ligand and direct inhibitor of human
telomerase. Nucleic Acids Res., 38, 5797–5806.
9. Schoeftner,S. and Blasco,M.A. (2008) Developmentally regulated
transcription of mammalian telomeres by DNA-dependent RNA
polymerase II. Nat. Cell Biol., 10, 228–236.
10. Azzalin,C.M., Reichenbach,P., Khoriauli,L., Giulotto,E. and
Lingner,J. (2007) Telomeric repeat containing RNA and RNA
surveillance factors at mammalian chromosome ends. Science,
318, 798–801.
11. Reichenbach,P., Hoss,M., Azzalin,C.M., Nabholz,M., Bucher,P.
and Lingner,J. (2003) A human homolog of yeast Est1 associates
with telomerase and uncaps chromosome ends when
overexpressed. Curr. Biol., 13, 568–574.
12. Snow,B.E., Erdmann,N., Cruickshank,J., Goldman,H., Gill,R.M.,
Robinson,M.O. and Harrington,L. (2003) Functional conservation
of the telomerase protein Est1p in humans. Curr. Biol., 13,
698–704.
13. Redon,S., Reichenbach,P. and Lingner,J. (2007) Protein RNA
and protein protein interactions mediate association of human
EST1A/SMG6 with telomerase. Nucleic Acids Res., 35,
7011–7022.
14. Chawla,R., Redon,S., Raftopoulou,C., Wischnewski,H., Gagos,S.
and Azzalin,C.M. (2011) Human UPF1 interacts with TPP1 and
telomerase and sustains telomere leading-strand replication.
EMBO J., 30, 4047–4058.
15. Farnung,B.O., Brun,C.M., Arora,R., Lorenzi,L.E. and
Azzalin,C.M. (2012) Telomerase efﬁciently elongates highly
transcribing telomeres in human cancer cells. PLoS One, 7,
e35714.
16. Pfeiffer,V. and Lingner,J. (2012) TERRA promotes telomere
shortening through exonuclease 1-mediated resection of
chromosome ends. PLoS Genet., 8, e1002747.
17. Labranche,H., Dupuis,S., Bendavid,Y., Bani,M.R., Wellinger,R.J.
and Chabot,B. (1998) Telomere elongation by hnrnp a1 and a
derivative that interacts with telomeric repeats and telomerase.
Nat. Genet., 19, 199–202.
18. Ding,J., Hayashi,M.K., Zhang,Y., Manche,L., Krainer,A.R. and
Xu,R.M. (1999) Crystal structure of the two-RRM domain of
hnRNP A1 (UP1) complexed with single-stranded telomeric
DNA. Genes Dev., 13, 1102–1115.
19. Ishikawa,F., Matunis,M.J., Dreyfuss,G. and Cech,T.R. (1993)
Nuclear proteins that bind the pre-mRNA 30 splice site sequence
r(UUAG/G) and the human telomeric DNA sequence
d(TTAGGG)n. Mol. Cell. Biol., 13, 4301–4310.
20. de Silanes,I.L., d’Alcontres,M.S. and Blasco,M.A. (2010) TERRA
transcripts are bound by a complex array of RNA-binding
proteins. Nat. Commun., 1, 1–9.
21. Ford,L.P., Wright,W.E. and Shay,J.W. (2002) A model for
heterogeneous nuclear ribonucleoproteins in telomere and
telomerase regulation. Oncogene, 21, 580–583.
22. Ford,L.P., Suh,J.M., Wright,W.E. and Shay,J.W. (2000)
Heterogeneous nuclear ribonucleoproteins C1 and C2 associate
with the RNA component of human telomerase. Mol. Cell. Biol.,
20, 9084–9091.
23. Flynn,R.L., Centore,R.C., O’Sullivan,R.J., Rai,R., Tse,A.,
Songyang,Z., Chang,S., Karlseder,J. and Zou,L. (2011) TERRA
and hnRNPA1 orchestrate an RPA-to-POT1 switch on telomeric
single-stranded DNA. Nature, 471, 532–536.
24. Konkel,L.M., Enomoto,S., Chamberlain,E.M., McCune-
Zierath,P., Iyadurai,S.J. and Berman,J. (1995) A class of single-
stranded telomeric DNA-binding proteins required for Rap1p
localization in yeast nuclei.Proc. Natl Acad. Sci. USA, 92,
5558–5562.
25. Cristofari,G., Adolf,E., Reichenbach,P., Sikora,K., Terns,R.M.,
Terns,M.P. and Lingner,J. (2007) Human telomerase RNA
accumulation in Cajal bodies facilitates telomerase recruitment to
telomeres and telomere elongation. Mol. Cell, 27, 882–889.
Nucleic Acids Research, 2013, Vol. 41, No. 19 9127
26. Zhang,Q.S., Manche,L., Xu,R.M. and Krainer,A.R. (2006)
hnRNP A1 associates with telomere ends and stimulates
telomerase activity. RNA, 12, 1116–1128.
27. Burd,C.G. and Dreyfuss,G. (1994) RNA binding speciﬁcity of
hnRNP A1: signiﬁcance of hnRNP A1 high-afﬁnity binding sites
in pre-mRNA splicing. EMBO J., 13, 1197–1204.
28. Cristofari,G., Reichenbach,P., Regamey,P.O., Banﬁ,D.,
Chambon,M., Turcatti,G. and Lingner,J. (2007) Low- to high-
throughput analysis of telomerase modulators with Telospot. Nat.
Methods, 4, 851–853.
29. Kim,N.W., Piatyszek,M.A., Prowse,K.R., Harley,C.B.,
West,M.D., Ho,P.L., Coviello,G.M., Wright,W.E., Weinrich,S.L.
and Shay,J.W. (1994) Speciﬁc association of human telomerase
activity with immortal cells and cancer. Science, 266, 2011–2015.
30. Porro,A., Feuerhahn,S., Reichenbach,P. and Lingner,J. (2010)
Molecular dissection of TERRA biogenesis unveils the presence
of distinct and multiple regulatory pathways. Mol. Cell. Biol., 30,
4808–4817.
31. Zappulla,D.C., Roberts,J.N., Goodrich,K.J., Cech,T.R. and
Wuttke,D.S. (2009) Inhibition of yeast telomerase action by the
telomeric ssDNA-binding protein, Cdc13p. Nucleic Acids Res, 37,
354–367.
32. Kelleher,C., Kurth,I. and Lingner,J. (2005) Human protection of
telomeres 1 (POT1) is a negative regulator of telomerase activity
in vitro. Mol. Cell. Biol., 25, 808–818.
33. Lei,M., Zaug,A.J., Podell,E.R. and Cech,T.R. (2005) Switching
human telomerase on and off with hPOT1 protein in vitro.
J. Biol. Chem., 280, 20449–20456.
34. Latrick,C.M. and Cech,T.R. (2010) POT1-TPP1 enhances
telomerase processivity by slowing primer dissociation and aiding
translocation. EMBO J., 29, 924–933.
35. Takai,K.K., Kibe,T., Donigian,J.R., Frescas,D. and de Lange,T.
(2011) Telomere protection by TPP1/POT1 requires tethering to
TIN2. Mol. Cell, 44, 647–659.
36. Chen,L.Y., Redon,S. and Lingner,J. (2012) The human CST complex
is a terminator of telomerase activity. Nature, 488, 540–544.
9128 Nucleic Acids Research, 2013, Vol. 41, No. 19
